Arcadia Biosciences (RKDA) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
26 Jun, 2026Company overview and business model
Focuses on science-based innovation in consumer goods, notably Zola coconut water products after acquiring Zola in 2021.
Previously commercialized wheat products through food sales, trait licensing, and royalties.
Recent asset sales include the RS durum wheat trait to Corteva for $4M and the Good Wheat brand to Above Food Corp. for $3.7M.
Entered and terminated a merger agreement with Roosevelt Resources LP in 2024–2025.
In 2025, restructured agreements with Bioceres Crop Solutions, transferring certain soy traits and patents for $750,000.
Financial performance and metrics
Accumulated deficit, recurring net losses, and negative cash flow from operations as of December 31, 2025, and March 31, 2026.
Substantial doubt exists about the ability to continue as a going concern without additional financing.
Gross proceeds from the June 2026 private placement were approximately $4M; potential gross proceeds from full exercise of options could reach $7.4M.
Use of proceeds and capital allocation
Will not receive proceeds from stockholder resales; only from cash exercise of options.
Any proceeds from option exercises will be used for working capital and general corporate purposes.
Management has broad discretion over use of proceeds, which may not enhance results or stock price.
Latest events from Arcadia Biosciences
- Shareholders will vote on director election, equity issuance, reverse split, and governance proposals.RKDA
Proxy filing31 Jul 2026 - Net loss of $4.4M and low cash raise substantial doubt about ongoing operations.RKDA
Q1 202614 May 2026 - Zola revenues grew 17% year-over-year, but total revenues fell and further funding is needed.RKDA
Q4 202526 Mar 2026 - Q2 net income up 30% on asset sales and 42% Zola growth, but liquidity remains a concern.RKDA
Q2 20241 Feb 2026 - Registering 1.67M shares for resale, with proceeds for working capital amid going concern risk.RKDA
Registration Filing28 Jan 2026 - Q3 revenue up 18% with Zola sales surging 55% and net loss sharply reduced.RKDA
Q3 202414 Jan 2026 - All-stock merger gives Roosevelt 90% control, pivoting to major CCUS and EOR oil projects.RKDA
M&A Announcement11 Jan 2026 - Zola sales surged 46% in 2024, fueling growth as the business streamlined and prepared for a major transaction.RKDA
Q4 202426 Dec 2025 - Q1 2025 net income hit $2.6M as Zola sales soared, but liquidity risks persist.RKDA
Q1 202524 Nov 2025